These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30255136)

  • 1. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research.
    Gassmann D; Weiler S; Mertens JC; Reiner CS; Vrugt B; Nägeli M; Mangana J; Müllhaupt B; Jenni F; Misselwitz B
    Transplant Direct; 2018 Aug; 4(8):e376. PubMed ID: 30255136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review.
    Jin X; Zhang K; Fang T; Zeng X; Yan X; Tang J; Liang Z; Xie L; Zhao D
    Front Oncol; 2022; 12():951303. PubMed ID: 36119543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma.
    Abdelrahim M; Esmail A; Divatia MK; Xu J; Kodali S; Victor DW; Brombosz E; Connor AA; Saharia A; Elaileh A; Kaseb AO; Ghobrial RM
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892779
    [No Abstract]   [Full Text] [Related]  

  • 5. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
    Nordness MF; Hamel S; Godfrey CM; Shi C; Johnson DB; Goff LW; O'Dell H; Perri RE; Alexopoulos SP
    Am J Transplant; 2020 Mar; 20(3):879-883. PubMed ID: 31550417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
    Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
    Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab.
    Amjad W; Kotiah S; Gupta A; Morris M; Liu L; Thuluvath PJ
    J Clin Exp Hepatol; 2020; 10(2):185-187. PubMed ID: 32189935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
    Kang E; Martinez M; Moisander-Joyce H; Saenger YM; Griesemer AD; Kato T; Yamashiro DJ; Remotti H; Gartrell RD
    Pediatr Transplant; 2022 May; 26(3):e14209. PubMed ID: 34907641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
    Qiu J; Tang W; Du C
    Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma.
    Friend BD; Venick RS; McDiarmid SV; Zhou X; Naini B; Wang H; Farmer DG; Busuttil RW; Federman N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
    Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
    J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients.
    Trager MH; Coley SM; Dube G; Khan S; Ingham M; Samie FH; Geskin LJ; McDonnell D; Brouder D; Saenger Y; Carvajal R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.
    Fisher J; Zeitouni N; Fan W; Samie FH
    J Am Acad Dermatol; 2020 Jun; 82(6):1490-1500. PubMed ID: 31302190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience.
    Ghobrial RM; Farmer DG; Baquerizo A; Colquhoun S; Rosen HR; Yersiz H; Markmann JF; Drazan KE; Holt C; Imagawa D; Goldstein LI; Martin P; Busuttil RW
    Ann Surg; 1999 Jun; 229(6):824-31; discussion 831-3. PubMed ID: 10363896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(4):1-56. PubMed ID: 23074407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
    Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
    World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.
    Hurkmans DP; Verhoeven JGHP; de Leur K; Boer K; Joosse A; Baan CC; von der Thüsen JH; van Schaik RHN; Mathijssen RHJ; van der Veldt AAM; Hesselink DA
    J Immunother Cancer; 2019 Jul; 7(1):182. PubMed ID: 31300068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B; McBride A; Scott AJ
    Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of checkpoint inhibitors in liver transplant recipients.
    Munker S; De Toni EN
    United European Gastroenterol J; 2018 Aug; 6(7):970-973. PubMed ID: 30228883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.